Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis

Diabetes Research and Clinical Practice

Volumn 116, Issue , 2016, Pages 86-95

  Kim, Yeong Gi ^a,b   Min, Se Hee ^a   Hahn, Seokyung ^c   Oh, Tae Jung ^a   Park, Kyong Soo ^a   Cho, Young Min ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Insulin; Meta analysis; Systematic review; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; PLACEBO; SAXAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT GAIN; ANALYSIS; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; WEIGHT GAIN;

EID: 84964963395     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.03.011     Document Type: Article

References (37)

1. Guariguata L., Whiting D.R., Hambleton I., Beagley J., Linnenkamp U., Shaw J.E. Global estimates of diabetes prevalence in adults for 2013 and projections for 2035. Diabetes Res Clin Pract 2014, 103(2):137-149.
2. Defronzo R.A. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58(4):773-795.
3. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004, 53(Suppl. 3):S16-S21.
4. American Diabetes A. Standards of medical care in diabetes-2014. Diabetes Care 2014, 37(Suppl. 1):S14-S80.
5. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379.
6. Raccah D., Bretzel R.G., Owens D., Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough - what next?. Diabetes Metab Res Rev 2007, 23(4):257-264.
7. Holman R.R., Farmer A.J., Davies M.J., Levy J.C., Darbyshire J.L., Keenan J.F., et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009, 361(18):1736-1747.
8. Ahren B. Insulin plus incretin: a glucose-lowering strategy for type 2-diabetes. World J Diabetes 2014, 5(1):40-51.
9. Cho Y.M., Fujita Y., Kieffer T.J. Glucagon-like peptide-1: glucose homeostasis and beyond. Annu Rev Physiol 2014, 76:535-559.
10. Seino Y., Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 2013, 4(2):108-130.
11. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368(9548):1696-1705. [Epub 2006/11/14].
12. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91(1):301-307.
13. Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36(8):741-744.
14. Cho Y.M., Merchant C.E., Kieffer T.J. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther 2012, 135(3):247-278. [Epub 2012/06/05].
15. Eng C., Kramer C.K., Zinman B., Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014.
16. Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011, 13(1):7-18.
17. Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007, 30(6):1335-1343.
18. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151(4):W65-W94. [Epub 2009/07/23].
19. Rosenstock J., Rendell M.S., Gross J.L., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009, 11(12):1145-1152.
20. Yki-Jarvinen H., Rosenstock J., Duran-Garcia S., Pinnetti S., Bhattacharya S., Thiemann S., et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: A >52-week randomized, double-blind study. Diabetes care [Internet] 2013, 12:3875-3881. Available from: .
21. Barnett A.H., Charbonnel B., Donovan M., Fleming D., Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012, 28(4):513-523.
22. Vilsbøll T., Rosenstock J., Yki-Järvinen H., Cefalu W.T., Chen Y., Luo E., et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab [Internet] 2010, 2:167-177. Available from: .
23. Merck Sharp & DohmeCorp Study of sitagliptin for the treatment of type 2 diabetes mellitus with inadequate glycemic control on insulin (MK-0431-260) http://clinicaltrialsgov/ct2/show/results/NCT01462266?term=NCT01462266%26rank=1.
24. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration [updated March 2011]. Version 5.1.0. [Available from: <>]. http://www.cochrane-handbook.org.
25. Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50(6):1148-1155.
26. Kadowaki T., Tajima N., Odawara M., Minamide T., Kawashima M., Yanagida D., et al. Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetol Int 2013, 4(3):160-172.
27. Kaku K., Mori M., Kanoo T., Katou M., Seino Y. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opin Pharmacother 2014, 15(15):2121-2130.
28. Kothny W., Foley J., Kozlovski P., Shao Q., Gallwitz B., Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013, 15(3):252-257.
29. Nauck M.A., Vilsboll T., Gallwitz B., Garber A., Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009, 32(Suppl. 2):S223-S231.
30. Ahren B., Schweizer A., Dejager S., Dunning B.E., Nilsson P.M., Persson M., et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009, 94(4):1236-1243.
31. He Y.L., Foteinos G., Neelakantham S., Mattapalli D., Kulmatycki K., Forst T., et al. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. Diabetes Obes Metab 2013, 15(12):1111-1119.
32. Mori Y., Taniguchi Y., Matsuura K., Sezaki K., Yokoyama J., Utsunomiya K. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. Diabetes Technol Ther 2011, 13(7):699-703.
33. Seufert J., Pegelow K., Bramlage P. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. Vasc Health Risk Manag 2013, 9:711-717.
34. Hollander P., Raslova K., Skjoth T.V., Rastam J., Liutkus J.F. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab 2011, 13(3):268-275.
35. Aroda V.R., Henry R.R., Han J., Huang W., DeYoung M.B., Darsow T., et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012, 34(6):1247-1258.
36. Hong E.S., Khang A.R., Yoon J.W., Kang S.M., Choi S.H., Park K.S., et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab 2012, 14(9):795-802.
37. Frandsen C.S., Madsbad S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with type 2 diabetes: a review. Diabet Med 2014, 31(11):1293-1300.